small molecule

IBRANCE

PALBOCICLIB

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry

CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand name	IBRANCE
Active ingredient	PALBOCICLIB
Strength	75MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	November 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
11065250*PED	February 2037	—
11065250	August 2036	product
10723730*PED	August 2034	—
10723730	February 2034	substance, product
RE47739*PED	September 2027	—
RE47739	March 2027	substance, product

Regulatory exclusivity

Code	Expires
PED	March 2029
M-14	September 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Pfizer